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The World Health Organization (WHO) in the year 2010 defined mixed adenoneuroendocrine carcinoma (MANEC) as neoplasms involving both the neuroendocrine and 
the epithelial components. The diagnostic criteria of MANEC 
are as follows: Both the components must be malignant and 
each component has to comprise at least 30% of the tumor [1]. 
Cordier in the year 1924 published the first report on a mixed 
exocrine and a neuroendocrine tumor (NET) [2]. Since then, 
few developments have been made in this field. Composite 
carcinoid, argentaffin cell adenocarcinoma, mucin-producing 
carcinoid, goblet cell carcinoid, adenocarcinoid, and small cell 
undifferentiated carcinoma were some of the terminologies used 
earlier to describe this entity.
The classification of these tumors was suggested in 1987 by 
Lewin as collision, combined, and amphicrine tumors [3]. In the 
year 2000, the WHO classified these endocrine tumors as mixed 
exocrine-endocrine tumors when each component represents 
at least 30% of the lesion [4]. Finally, in 2010, the WHO 
classification named these tumors as MANECs [5].
It is important to note that, according to this nomenclature, if a 
particular component does not form 30% of the lesions, it cannot 
be categorized as a mixed tumor but rather an adenoma or NETs 
separately. This entity has been subdivided into different categories 
based on the degree of differentiation of each component: High-
grade malignant type and intermediate-grade malignant type, 
(intermediate type also includes amphicrine carcinoma) [6]. We 
present case series with a histological diagnosis of MANEC and 
its management.
CASE REPORTS
Case 1
A 58-year-old gentleman presented a history of pain abdomen 
(dull aching) and intermittent bleeding per rectum for 4 months. 
On clinical examination, vital signs were stable with a pulse 
rate of 76/min and blood pressure of 126/84 mmHg. Pallor was 
present with no significant findings on per abdomen and rectal 
examination. Except for anemia with hemoglobin of 8 g/dL, all 
other blood investigations were normal. Colonoscopy revealed 
a nodular thick friable growth causing narrowing of the colonic 
lumen (ascending colon). The biopsy showed features of a poorly 
differentiated carcinoma, while neuroendocrine differentiation 
could not be excluded. Serum carcinoembryonic antigen levels 
were 7.19 ng/dL (normal value <5 ng/dL). Contrast-enhanced 
computed tomography (CECT) of the abdomen and pelvis 
revealed circumferential enhancing thickening of the proximal 
ascending colon for a length of 5 cm with significant luminal 
obstruction, with no evidence of distant metastases.
The patient was transfused with two units of packed red blood 
cells. He then underwent a right radical hemicolectomy (Fig. 1). 
The final histopathology report showed MANEC extending 
microscopically into the serosa with a pathological staging of 
pT3 N1a Mx. The neoplastic cells were positive to cytokeratin 20 
(CK20), caudal type homeobox 2 (CDX2), and synaptophysin and 
were negative for chromogranin. Occasional cells were positive 
for CD56 with Ki proliferative index of 60–70%. The patient 
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was on adjuvant treatment with irinotecan and capecitabine. 
Response assessment was done after 4 cycles with positron 
emission tomography-CT (PET-CT) scan which showed multiple 
periportal, retroperitoneal, and mesenteric and mediastinal lymph 
nodes. In view of progressive disease, the regimen was changed 
to capecitabine and oxaliplatin. Disease remained stable after 
3 cycles. Hence, three more cycles of capecitabine and oxaliplatin 
were planned. At present, the patient is on the same regimen.
Case 2
A 60-year-old female presented with a history of gradually 
increasing jaundice for 3 months associated with nausea and 
vomiting. On clinical examination, icterus was present with 
palpable gallbladder on abdomen examination. No clinical signs 
of cholangitis were present. No other significant findings were 
noted. Biochemical tests revealed a conjugated hyperbilirubinemia 
with serum bilirubin levels of 11 mg/dL and direct bilirubin 
of 8.6 mg/dL. Serum gamma-glutamyl transpeptidase and 
serum alkaline phosphatase levels were 72 IU/L (normal value 
0–35 IU/L) and 67 IU/L (normal value 0–35 IU/L), respectively, 
and a serum albumin of 3.6 g/dL with other liver function test 
parameters within normal limits. Subsequent CECT scan revealed 
a dilated common bile duct (C with abrupt narrowing of distal bile 
duct with an ill-defined enhancing mass lesion proximal to the 
pancreaticobiliary junction causing dilatation of the intrahepatic 
biliary radicles and pancreatic duct likely a neoplastic stricture). 
Endoscopic retrograde cholangio pancreatography (ERCP) was 
done and brush cytology revealed atypical cells suspicious of 
malignancy.
She underwent a Whipple’s pancreaticoduodenectomy and the 
histopathology was reported as MANEC of intermediate grade 
with tumor extension into the pancreas and pathologic stage 
of pT3b N0 Mx. A ×10 view of hematoxylin and eosin stained 
tissue demonstrating the neuroendocrine and adenocarcinoma 
component of tumor is shown in Fig. 2. Immunohistochemistry 
report shows positivity for CK7, synaptophysin, chromogranin, 
and CD56. The Ki proliferative index was 8–10% (Fig. 3). The 
patient is presently on adjuvant chemotherapy (cisplatin and 
etoposide) without any evidence of recurrence after 4 cycles of 
chemotherapy.
Case 3
A 56-year-old gentleman presented with a complaint of jaundice 
of 1 month duration with loss of appetite for 15 days. On clinical 
examination, icterus was present with palpable gallbladder on 
abdomen examination. No other significant findings were noted. 
Biochemical tests revealed a conjugated hyperbilirubinemia 
with serum bilirubin levels of 8 mg/dL and direct bilirubin of 
6.7 mg/dL. Other blood tests and liver function test values were 
within normal limits. A CECT scan revealed a dilated common 
bile duct with abrupt narrowing of distal bile duct with an ill-
defined enhancing mass in the distal bile duct causing dilatation 
of the intrahepatic biliary radicles, likely a neoplastic etiology. 
Figure 1: Specimen photograph of right hemicolectomy with tumor
Figure 2: ×10 view of hematoxylin and eosin stained tissue 
demonstrating the neuroendocrine and adenocarcinoma component 
of tumor
Figure 3: (a) ×10 view of cytokeratin staining demonstrating a 
granular pattern with 3 + positivity; (b) ×10 view of synaptophysin 
staining demonstrating a membranous type with 3 + positivity; 
(c) ×10 view of chromogranin staining demonstrating a granular 
cytoplasmic pattern; (d) ×40 view of Ki 67 staining demonstrating 
a nuclear pattern
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ERCP was done and biopsy revealed atypical cells suspicious of 
malignancy.
He underwent Whipple’s pancreaticoduodenectomy, and 
the final histopathology report was suggestive of MANEC with 
predominant adenocarcinoma component and pathologic stage of 
pT3b N0 Mx. The patient received 3 cycles of adjuvant gemcitabine-
based chemotherapy. As he could not tolerate the treatment, further 
chemotherapy was not given and lost to follow up.
DISCUSSION
In the era of personalized medicine, diagnostic modality we choose 
and treatment decisions we make have a huge impact on prognosis. 
When such is the scenario, making the best use of available 
modern diagnostic tools and tailored therapy does influence the 
survival. In gastrointestinal malignancies, particularly MANEC, 
the neuroendocrine component does influence the biology of a 
tumor based on available case studies. Diagnosis of this entity 
is made by the use of immunohistochemistry. No particular 
locus is identified yet, to make use of targeted therapy, unlike in 
adenocarcinoma. No large studies available yet to understand the 
exact nature of this entity. MANEC has been described in various 
sites such as stomach, colon [7], pancreas [8], esophagus [9], 
appendix [10], rectum [11], and cervix [12]. Irrespective of a site 
of the tumor, prognosis and treatment have remained the same.
MANEC tumors are fluorodeoxyglucose avid, and gallium 
DOTANOC PET/CT has a role in staging and assessing the 
recurrence or progression [9]. While planning the management, 
the aggressiveness of this disease needs to be taken into account. 
For instance, MANEC of appendix needs to be treated with 
aggressive multimodality treatment with right hemicolectomy 
and adjuvant treatment rather than appendectomy alone [13]. 
Adjuvant chemotherapy regimen depends on higher grade and 
component of tumor (adeno or neuroendocrine). MANECs 
with a well-differentiated NET component and adenocarcinoma 
component can be treated as adenocarcinoma and a poorly 
differentiated NEC component can be treated as NECs [6].
Patta reported a high response rate to cisplatin and etoposide in 
patients with high-grade neuroendocrine colorectal tumors [14]. 
The National Comprehensive Cancer Network recommends 
cisplatin or carboplatin and etoposide (based on protocols for 
small cell lung carcinoma) [15]. In our series, treatment was based 
on higher component and more aggressive component. Other 
protocols are based on cetuximab, FOLFOX, and octreotide or 
bevacizumab and FOLFOX6. In the case of hepatic metastases, 
transarterial chemoembolization with doxorubicin has been 
reported [16]. Other agents such as mitomycin C or streptozocin 
have been used with different success rates. The role of new drugs 
such as everolimus or sunitinib needs to be defined. Radiotherapy 
could be considered in patients at high risk of local recurrence.
Research studies are required to understand the biology of the 
tumour, to predict the natural history of this entity. Cases reported 
in our series belong to elderly age group. The interval between 
detection of a primary tumor and metastases has been 2.5 months 
in one of the reports [17] when compared to 3 months in the case 
1 in the case history. Reason for aggressiveness of the disease 
is mostly due to the neuroendocrine component of tumor [18]. 
Follow-up surveillance needs to be more aggressive due to the 
belligerent nature of the disease. Serum chromogranin levels along 
with a marker for epithelial component need to be used during 
surveillance, as they are elevated in the metastatic or recurrent 
setting of MANEC tumors [19]. MANECs possibly emanate 
from bidirectionally differentiated multipotent stem cells. No 
clear origin of MANEC has been proposed till date. One of the 
theories proposed for the transformation of the adenocarcinoma 
component into the neuroendocrine phenotype is the mutation in 
SMARCA4 [18,20].
Hence, research is needed to assess the origin of these tumors. 
In one of the large series, median overall survival was around 
21 months, and authors reported a highly significant survival 
benefit with adjuvant treatment rather than surgery alone. They 
had also reported no significant difference in the survival between 
platinum compounds and etoposide when compared to platinum 
compounds and 5-fluorouracil [21]. Further studies are warranted 
to predict the responsiveness to the different line of treatment.
CONCLUSION
Histology per se determines prognosis in certain clinical situations. 
MANEC is one such condition which has a relatively poor 
prognosis. Optimum mode of management is yet to be proposed, 
as there are no clear guidelines regarding its management. Further 
studies are required first to assess the origin of these tumors and 
to find the ideal mode of management.
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